Alivus Life Sciences Limited (NSE:ALIVUS)
India · Delayed Price · Currency is INR | Market Cap | 138.20B +14.0% |
| Revenue (ttm) | 25.12B +10.5% |
| Net Income | 5.44B +23.1% |
| EPS | 44.23 +23.1% |
| Shares Out | 122.74M |
| PE Ratio | 25.46 |
| Forward PE | 22.78 |
| Dividend | 5.00 (0.45%) |
| Ex-Dividend Date | Sep 1, 2025 |
| Volume | 86,959 |
| Average Volume | 124,943 |
| Open | 1,122.90 |
| Previous Close | 1,121.30 |
| Day's Range | 1,069.90 - 1,148.40 |
| 52-Week Range | 819.00 - 1,225.10 |
| Beta | 0.06 |
| RSI | 71.17 |
| Earnings Date | May 14, 2026 |
About Alivus Life Sciences
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health,... [Read more]
Financial Performance
In fiscal year 2025, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.
Financial StatementsNews
Alivus Life Sciences Transcript: Q3 25/26
Q3FY26 saw record revenue and margins, led by a strong CDMO rebound and robust API generics growth. High single-digit revenue growth and 30%-32% margins are guided for FY26-FY27, with double-digit growth expected from FY28 as new capacity ramps up.
Alivus Life Sciences Transcript: Q2 25/26
Q2 FY 2026 saw 16% YoY revenue growth to INR 588 crore, with strong non-GPL and new product launches driving performance. Margins improved, and guidance for high single-digit growth is reaffirmed, with H2 expected to benefit from a rebound in GPL and CDMO segments.
Alivus Life Sciences Transcript: Q1 25/26
Q1 FY26 saw 2.2% YoY revenue growth to INR 602 crore, with strong margins and robust cash flow. Non-GPL business led growth, while GPL is expected to recover in H2. CDMO ramp-up and new launches support a positive outlook, with margins guided at 28–30%.
Alivus Life Sciences Transcript: Q4 24/25
Q4 FY2025 saw 21.1% revenue growth and a 32.1% EBITDA margin, with strong performance across all regions and segments. FY2026 guidance anticipates mid-teens volume growth but high single-digit revenue growth due to pricing pressure, with margins expected to remain robust.
Alivus Life Sciences Transcript: Q3 24/25
Q3 FY25 saw 12% YoY and 27% QoQ revenue growth, with strong margins and 18% volume growth. CDMO showed QoQ recovery, while new launches and expansion projects are set to drive future growth. Cash reserves remain robust, and CapEx is focused on R&D and capacity.
Alivus Life Sciences Transcript: Q2 24/25
Q2 FY2025 saw a 14.9% YoY revenue decline due to a temporary production halt, but gross margins improved to 55.6% and EBITDA margin to 28.2%. FY2025 revenue growth is now guided at high single digits, with strong H2 recovery expected and new CDMO projects set to drive future growth.
Alivus Life Sciences Transcript: Q1 24/25
Q1 FY 2025 saw a 9.7% sequential revenue increase, broad-based growth, and stable margins despite lower gross margin due to loss of PLI benefit. Capacity expansions and a strong pipeline support a positive outlook, while a pollution notice at the main facility is being addressed.